Caribou Biosciences, Inc. (CRBU)

Over the past six months, Caribou Biosciences' stock has experienced several notable events. In November 2025, clinical data for vispa-cel and initial data for CB-011 boosted confidence despite a reported EPS of -$0.30 for Q3 2025. On March 5, 2026, the company reported its Fourth Quarter and Full Year 2025 financial results, initially gaining 6% following the earnings beat, but enthusiasm was tempered by the need for additional financing. On March 17, 2026, an article highlighted Caribou's 80% advance over the past year due to strong allogeneic CAR-T data. On March 31, 2026, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, positively impacting the stock. In the 30 days leading up to April 9, 2026, the stock declined approximately 10%, while in the past quarter, it rose about 12%. As of April 8, 2026, the share price was $1.95, representing a 117.76% increase over the price on April 9, 2025.

Information regarding specific demand seasonality for Caribou Biosciences' products and services is not explicitly available. Demand for its potential future products would likely be driven by disease prevalence and treatment efficacy rather than traditional seasonal patterns. The company's financial performance and stock events can be influenced by the timing of clinical trial results, regulatory milestones, and financial reporting.

Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing allogeneic CAR-T and CAR-NK cell therapies for hematologic malignancies and autoimmune diseases. The company operates within the Pharmaceuticals & Biotech sector and Biotechnology industry, leveraging its proprietary Cas12a chRDNA technology to create armored cell therapies. Its major product candidates include vispa-cel for relapsed or refractory B cell non-Hodgkin lymphoma, CB-011 for relapsed or refractory multiple myeloma (with RMAT designation), and CB-012 for acute myeloid leukemia (with Fast Track and Orphan Drug designations).

Caribou Biosciences, Inc. is headquartered in Berkeley, California, United States. The company's business segment for developing allogeneic CAR-T and CAR-NK cell therapies operates in the United States and the Rest of the World, with the United States deriving maximum revenue.

Caribou Biosciences is recognized as a pioneer in CRISPR genome editing and nucleic acid biology. Its reputation has been positively influenced by strong clinical data from its allogeneic CAR-T programs, including vispa-cel and CB-011, and the FDA granting RMAT designation to CB-011. However, concerns about cash burn and the need for additional financing have tempered enthusiasm, leading to some stock declines. Despite these financial concerns, analyst consensus remains a "Buy" with significant upside potential.

Caribou Biosciences has a mixed ownership structure. Institutional investors hold approximately 12.73% to 77.51% of the stock, with major holders including Pfizer Inc., Vanguard Group Inc., and BlackRock, Inc. Insiders own approximately 4.78% to 8.28% of the stock, with CEO Rachel E. Haurwitz holding a significant number of shares; insiders have sold more stock than they have bought in the past three months. Public companies and retail investors collectively own a substantial portion, with some data suggesting approximately 68.83% is held by retail investors.